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摘  要 











要癌症之一，胶质瘤是中枢神经系统 常见的肿瘤。本论文对 54 例结肠癌
组织和 56 例胶质瘤组织进行了分析，首先通过免疫组化的方法鉴定
β-catenin 与 Axin 两种蛋白水平在这两种肿瘤组织中是否存在异常。然后我
们根据 AXIN1 基因的 DNA 序列，设计了覆盖 AXIN1 基因所有外显子序列






















1、正常结肠组织中β-catenin 染色阴性，没有β-catenin 的积累；37 例结肠
癌组织中有 59.4% (22/37)的组织中存在β-catenin 的积累，包括胞浆的积
累和转移至胞核的积累；β-catenin 的积累在不同级别的结肠癌中都有很
大比例的存在，说明β-catenin 的积累在结肠癌发生中起着重要作用。 
2、正常结肠组织中 Axin 染色阳性；37 例结肠癌有 62.2% (23/37)的组织中
Axin 免疫组化染色阴性；随着肿瘤级别的升高，Axin 阴性率呈上升的趋
势，说明 Axin 在结肠癌起着肿瘤抑制因子的作用。 
3、54 例结肠癌中 AXIN1 基因存在 14.8% (8/54)的有义/无义点突变，表明
AXIN1 基因在结肠癌中存在一定的突变发生频率；75% (6/8)的 AXIN1
基因发生突变的组织中有β-catenin 的积累，表明结肠癌中 AXIN1 基因
的突变与β-catenin 的积累有关。 
4、正常胶质瘤组织中胶质细胞β-catenin 染色阴性，没有β-catenin 的积累；
56 例胶质瘤中仅有 3.5% (2/56)的组织中有β-catenin 的积累，表明胶质瘤
中β-catenin 的积累不是导致胶质瘤发生的主要因素。 
5、 胶质瘤癌旁组织中正常胶质细胞 Axin 染色阴性；Axin 在高达 35.7% 
(20/56)的胶质瘤胶质细胞中染色阳性，表明 Axin 水平异常与胶质瘤的发
生有关。 
6、29 例胶质瘤中 AXIN1 基因存在高达 34.4% (10/29)的有义点突变，而且
多发生在 DIX 结构域，表明 Axin 的 DIX 结构域在胶质瘤发生中的重要
性；高级别的胶质瘤 Axin 染色阳性率高，发生突变的频率也高，说明在
胶质瘤中 AXIN1 基因突变与 Axin 蛋白水平增高和胶质瘤的发生有关。 
7、结肠癌和胶质瘤中由于 AXIN1 基因发生点突变导致 Axin 功能发生改变
的比率都高达 80%以上，通过 Wnt、JNK 或者 p53 信号途径，不同程度、
















因；AXIN1 基因突变频繁地发生在结肠癌和胶质瘤中，检测 AXIN1 基因的
突变可能为结肠癌和胶质瘤提供一种新的分子诊断手段。鉴于 Axin 突变能






































Wnt and JNK signaling pathways are composed of proteins encoded by a 
series of oncogenes and tumor suppress genes, these proteins restrict and 
cooperate with each other, playing important roles in cell shape, cell 
movement, cell adhesion, cell proliferation, differentiation and development. 
Disorderliness of the signaling network is tied up with oncogenesis. Axin was 
initially identified as an axis inhibitor; it is also a very important tumor 
suppressor. As a scaffold protein, Axin has many binding domains, through 
which it interacts with many important components of Wnt and JNK signaling 
pathways, to regulate the balance of the signaling transduction together with 
other factors. Additionally, Axin participates in some other critical signaling 
pathways such as p53 signaling pathway, TGF-β signaling pathway, and so on. 
The facts that Axin participates in Wnt, JNK, p53 and other important 
signaling pathways to regulate cell fate including cell growth, proliferation, 
oncogenesis etc., arose our interest to study the relationship between Axin and 
human oncogenesis. 
Cancer is a kind of grisly disease hurtful to human health. Colorectal 
cancer is one of the mainly lethiferous human cancers, and glioma is the most 
frequent tumor in the central nervous system. In this thesis, 54 samples of 
colorectal cancer tissues and 56 samples of glioma tissues were collected for 
analysis. Immunohistochemistry analysis was employed with antibody of 
β-catenin and Axin to detect if abnormity of the levels of these two proteins 
occurred in these samples. The genomic DNA was extracted from the 54 


















were employed with the genomic DNA and 23 sets of primers against introns 
that encompassed the whole coding region of AXIN1, followed by 
single-strand conformation polymorphism (SSCP) analysis. After subcloning 
and sequencing analysis of the reamplified DNA from the aberrant bands, we 
got the mutated sites of AXIN1 gene from these tumor samples. The 
mammalian expression vectors containing the point mutations of Axin were 
constructed by site-direct mutagenesis method. In order to identify whether 
mutated Axin changed the normal functions of wild type Axin and thus 
contributed to the development of these cancers, experiment techniques of 
biochemistry, molecular biology and cell biology, including cell transfection, 
luciferase reporter gene assay, co-immunoprecipitation, immunokinase assay 
were used to analyze the functions of the point mutants.  
The results of these studies include: 
1. Normal colorectal tissues  showed  negative staining of β-catenin, 
indicating no β-catenin accumulations; β-catenin accumulations were 
detected in 59.4% (22/37) of the colorectal cancer tissues; the 
accumulations occurred at a commonly high ratio in different grade of the 
tumor samples. This suggested that β-catenin accumulations contributed to 
the development of colorectal cancers. 
2. Normal colorectal tissues  showed  positive staining of Axin; lower levels 
of Axin were detected in 62.2% (23/37) of the colorectal cancer tissues; it 
appeared that the higher of the tumor’s grade was, the higher of the 
negative ratio of Axin’s immunohistochemistry, suggesting that Axin acted 
as a tumor suppressor in colorectal cancers. 


















the colorectal cancer tissues, indicating that certain frequency of AXIN1 
gene mutations occurred in colorectal cancers; the fact that 75% (6/8) of 
the missense mutations occurred in the tissues with β-catenin 
accumulations suggested that AXIN1 gene mutations were implicated in 
β-catenin accumulations in colorectal cancer tussues. 
4. Immunohistochemistry of β-catenin was negative in normal glioblasts, 
indicating no β-catenin accumulations; β-catenin accumulations were 
detected in only 3.5% (2/56) of the glioma tussues, suggesting that the 
accumulation of β-catenin was not an important cause in the development 
of gliomas. 
5. Immunohistochemistry of Axin was negative in normal glioblasts; 
overexpressions of Axin were detected in 35.7% (20/56) of the glioma 
tissues, suggesting that the abnormity of Axin were implicated in the 
development of gliomas. 
6. Missense point mutations of AXIN1 gene were detected in 34.4% (10/29) 
of glioma tissues, and most of the mutations occurred in the DIX domain 
of Axin, suggesting that DIX domain of Axin played an important role in 
the development of gliomas; the higher levels of Axin were, the more 
frequently mutations occurred, suggesting that AXIN1 gene mutations 
were related with high levels of Axin and development of gliomas. 
7. Over 80% of the point mutations found in colorectal cancers and glioma 
tissues eliminated the normal functions of Axin through Wnt, JNK or p53 
signaling pathway(s) by different degree and in different ways.  
In conclusion, AXIN1 mutations contributed to the development of 


















these two kinds of cancers, which will provide a new way for the diagnosis 
and therapy for colorectal cancers and gliomas, respectively. 
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